A Phase 1 Study Of Tp-3654, An Orally-Delivered Pim Kinase Inhibitor, In Patients With Intermediate-2 Or High-Risk Primary Or Secondary MyelofibrosisClaudia Lebedinsky,Stephen P. Anthony,Golam Mohi,Huyuan Yang,Jian Mei, Edgar BraendleBLOOD(2020)引用 3|浏览8暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要